David Rosen is a partner and public policy lawyer with Foley & Lardner LLP. He has extensive experience in health law, life sciences and food and drug regulation, including a range of Food and Drug Administration (FDA) regulatory issues affecting prescription and over-the-counter pharmaceuticals, medical devices and biologics. He is co-chair of the firm’s Life Sciences Industry Team and is also a member of the firm’s Government & Public Policy Practice and the Health Care and Food & Beverage Industry Teams.

David was formerly a partner with two other law firms. He was also employed by the FDA for 14 years, progressing to various supervisory positions involving virtually all aspects related to the drug approval process, combination products, jurisdictional issues and related compliance activities.


David was recognized in the 2021 edition of The Best Lawyers in America© for his work within FDA Law, and has been Peer Review Rated™ as AV Preeminent®, the highest performance rating in Martindale-Hubbell's peer review rating system. In 2012 - 2016, The Legal 500 recognized David for his work in life sciences. In 2015 and 2016, he was named an IP Star by Managing Intellectual Property magazine. He has been a frequent speaker before national and international pharmaceutical industry associations on the ANDA submission and review process and on the IND and expedited drug development, review and approval processes. He has made presentations before investment analysts and managers of venture capital on the impact of FDA on the drug and biotech industry.


David is a member of the University of Connecticut School of Pharmacy Advisory Board.


David earned his J.D. at The Catholic University of America, Columbus School of Law (1991). He also holds a Bachelor of Science degree from the University of Connecticut School of Pharmacy (1978).


David is admitted to practice in the District of Columbia and Maryland.


  • “How to Respond to Consent Decrees,” BioPharm International, Vol. 25, Issue 5, May 1, 2012
  • “FDA Getting Tougher at the Border,” Pharmaceutical Compliance Monitor, December 14, 2011
  • “MX: Device Reuse and Safety,” Medical Device and Diagnostic Industry, October 19, 2011
  • "Next Steps for the U.S. Biosimilar Regulatory Scheme," Pharmaceutical Technology, March 2011